GlucodOX - Guggul-based Nutraceutical For AMPK Activation, Energy & Metabolic Support | Nutent Theraputics

AMPK activator pill


Activate AMPK. Activate Health

Introducing GlucodOX®— the only patented guggul-based nutraceutical for stimulating AMPK to support metabolic health and wellness.


Extends your “healthspan” by enhancing the body’s response to cellular and metabolic stress:

  • Optimizes cellular energy throughout the body
  • Helps restore the AMPK activation capacity that declines with aging and suboptimal lifestyle
  • Supports healthy glucose and cholesterol levels already within normal limits
  • Promotes healthy weight control and fat metabolism


GlucodOX Logo (light)


The metabolic master switch

  • Regulates cellular metabolism
  • Promotes healthy weight
  • Reduces fat
  • Reduces inflammation
  • Decreases glucose levels
Man Woman icon
  • Increases insulin sensitivity
  • Increases blood flow
  • Antioxidant
  • Controls Cholesterol
  • Supports healthy aging

How is GlucodOX different?

Most guggulsterones support normal lipid (cholesterol) and glucose (diabetes) metabolism. By stimulating AMPK, the patented formulation in GlucodOX takes guggulsterones further, adding longevity-promoting mechanisms much like metformin.

Golden Droplet

Activate efficacy

GlucodOX phosphorylation
GlucoDOX chart
GlucodOX chart for Cholesterol

Activate wellness

The powerful and proprietary complex in GlucodOX can help maintain and support:

• Optimal metabolic and physiologic health*
• Prolonged healthspan by helping to reduce the effects of aging and/or a suboptimal lifestyle (i.e, food, stress, sleep deprivation, etc)*
• Improved response to cellular and physiologic stress*

A safe and well-documented nutraceutical
Guggul resin has been used in traditional medicine for thousands of years. MCT oils occur naturally in foods such as coconut oils and are regularly consumed all over the world.

GlucodOX® is made from a unique optimized supercritical CO2 extraction methodology that enhances efficacy and bioavailability.

Customer Reviews

Based on 1 review

Five Stars

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. References: 1. Data on file. Nutent Therapeutics. 2. Claudel T, Staels B, Kuipers F. The farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler Thromb Vasc Biol. 2005;25(10):2020-2030. 3. Lage R, Dieguez C, Vidal-Puig A, Lopez M. AMPK: a metabolic gauge regulating whole-body energy homeostasis. Trends Mol Med. 2008;14:539-549. 4. Long YC, Zierath JR. AMP-activated protein kinase signaling in metabolic regulation. J Clin Invest. 2006;116:1776-1783. 5. Steinberg GR, Kemp BE. AMPK in health and disease. Physiol Rev. 2009;89:1025-1078. 6. Hardie DG, Hawley SA, Scott JW. AMP-activated protein kinase–development of the energy sensor concept. J Physiol. 2006;574:7-15. 7. Stayrook KR, Bramlett KS, Savkur RS, Ficorilli J, et al. Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology. 2005;146(3):984-991. 8. Lim CT, Kola B, Korbonits M. AMPK as a mediator of hormonal signaling. J Mol Endocrinol. 2010;44:87-97. 9. Osler ME, Zierath JR. Adenosine 5’-monophosphate-activated protein kinase regulation of fatty acid oxidation in skeletal muscle. Endocrinology. 2008;149:935-941. 10. Sharma B, Salunke R, Srivastava S, Majumder C, Roy P. Effects of guggulsterone isolated from Commiphora mukul in high fat diet induced diabetic rats. Food Chem Toxicol. 2009; 47(10):2631-2639. 11. Yang JY, Della-Fera MA, Baile CA. Guggulsterone inhibits adipocyte differentiation and induces apoptosis in 3T3-L1 cells. Obesity. 2008;16:16-22. 12. Rizzo G, Disante M, Mencarelli A, et al. The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo. Mol Pharmacol. 2006;70:1164-1173. 13. Nityanand S, Srivastava JS, Asthana OP. Clinical trials with gugulipid. A new hypolipidaemic agent. J Assoc Physicians India. 1989;37:323-328. 14. Gopal K, Saran RK, Nityanand S, et al. Clinical trial of ethyl acetate extract of gum gugulu (gugulipid) in primary hyperlipidemia. J Assoc Physicians India. 1986;34:249-251. 15. Agarwal RC, Singh SP, Saran RK, et al. Clinical trial of gugulipid–a new hypolipidemic agent of plant origin in primary hyperlipidemia. Indian J Med Res. 1986;84:626-634. 16. Cantó C, Gerhart-Hines Z, Feige JN, et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature. 2009;458:1056-1060. 17. Urizar NL, Liverman AB, Dodds DT, et al. A natural product that lowers cholesterol as an antagonist ligand for FXR. Science. 2002;296:1703-1706. 18. Salminen A, Kaarniranta K, Kauppinen A. Age-related changes in AMPK activation: role for AMPK phosphatases and inhibitory phosphorylation by upstream signaling pathways. Ageing Res Rev. 2016;28:15-26. 19. Salminen A, Kaarniranta K. AMP-activated protein kinase (AMPK) controls the aging process via an integrated signaling network. Ageing Res Rev. 2012;11:230-241. 20. Yang JY, Della-Fera MA, Rayalam S, Ambati S, Baile CA. Enhanced pro-apoptotic and anti-adipogenic effects of genistein plus guggulsterone in 3T3-L1 adipocytes. Biofactors. 2007;30:159-169. 21. Ramachandran C, Nair SM, Quirrin K-W, Melnick, SJ. Hypolipidemic effects of a proprietary Commiphora mukul gum resin extract and medium-chain triglyceride preparation (GU-MCT810). J Ev Comp Alt Med. 2013;18(4):248-256. https://doi. org/10.1177/2156587213488601. 22. Kunnumakkara AB, Banik K, Bordoloi D, et al. Googling the guggul (commiphora and boswellia) for prevention of chronic diseases. Front Pharmacol. 2018;9:686. doi:10.3389/fphar.2018.00686. 23. Dev S. Ethnotherapeutics and modern drug development: the potential of ayurveda. Curr Sci. 1997;73(11): 909-928. www.jstor.org/stable/24101288.


Subscribe to the Nutent Therapeutics Newsletter and receive a discount on your first order